Autophagy- An emerging target for melanoma therapy

Melanoma accounts for only 5% of all cancers but is the leading cause of skin cancer death due to its high metastatic potential. Patients with metastatic melanoma have a 10-year survival rate of less than 10%. While the clinical landscape for melanoma is evolving rapidly, lack of response to therapi...

Full description

Saved in:
Bibliographic Details
Published in:F1000 research 2016, Vol.5, p.1888
Main Authors: Ndoye, Abibatou, Weeraratna, Ashani T
Format: Article
Language:English
Subjects:
Cancer Therapeutics
Cell Growth & Division
Cell Signaling
Cellular Death & Stress Responses
Immunomodulation
Immunopharmacology & Hematologic Pharmacology
Leukocyte Signaling & Gene Expression
Medical Genetics
Melanoma
Pharmacogenomics
Review
Skin Cancers (incl. Melanoma & Lymphoma)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Melanoma accounts for only 5% of all cancers but is the leading cause of skin cancer death due to its high metastatic potential. Patients with metastatic melanoma have a 10-year survival rate of less than 10%. While the clinical landscape for melanoma is evolving rapidly, lack of response to therapies, as well as resistance to therapy remain critical obstacles for treatment of this disease. In recent years, a myriad of therapy resistance mechanisms have been unravelled, one of which is autophagy, the focus of this review. In advanced stages of malignancy, melanoma cells hijack the autophagy machinery in order to alleviate drug-induced and metabolic stress in the tumor microenvironment, thereby promoting resistance to multiple therapies, tumor cell survival, and progression.  Autophagy is an essential cellular process that maintains cellular homeostasis through the recycling of intracellular constituents. Early studies on the role of autophagy in cancer generated controversy as to whether autophagy was pro- or anti-tumorigenic. Currently, there is a consensus that autophagy is tumor-suppressive in the early stages of cancer and tumor-promoting in established tumors.  This review aims to highlight current understandings on the role of autophagy in melanoma malignancy, and specifically therapy resistance; as well as to evaluate recent strategies for therapeutic autophagy modulation.
ISSN:2046-1402
2046-1402
DOI:10.12688/F1000RESEARCH.8347.1